Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones

Annals of Medicine

Volumn 46, Issue 7, 2014, Pages 512-529

  Van Bambeke, Franҫoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Avarofloxacin; Delafloxacin; EDP 322; Finafloxacin; Nemonoxacin; Oritavancin; Solithromycin; Zabofloxacin

Indexed keywords

ACORAFLOXACIN; CETHROMYCIN; DELAFLOXACIN; FINAFLOXACIN; KETOLIDE; NEMONOXACIN; ORITAVANCIN; QUINOLONE DERIVATIVE; SOLITHROMYCIN; TELITHROMYCIN; ZABOFLOXACIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE; MACROLIDE; TRIAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG HALF LIFE; DRUG PROTEIN BINDING; GONORRHEA; HELICOBACTER INFECTION; HUMAN; LUNG ALVEOLUS MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; HUMANS; MACROLIDES; QUINOLONES; TRIAZOLES;

EID: 84910004816     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.935470     Document Type: Review

References (158)

1. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, et al. 10 x '20 Progress - development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685-94.
2. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4:185-91.
3. d'Urso de Souza Mendes C, de Souza Antunes AM. Pipeline of known chemical classes of antibiotics. Antibiotics. 2013;2:500-34.
4. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs. 2004;64:913-36.
5. Edelsberg J, Weycker D, Barron R, Li X, Wu H, Oster G, et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis. 2014;78:255-62.
6. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis. 2014;78:429-36.
7. Jones RN, Guzman-Blanco M, Gales AC, Gallegos B, Castro AL, Martino MD, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis. 2013;17:672-81.
8. Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:291-306.
9. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis. 2013;56:1310-18.
10. Limbago BM, Kallen AJ, Zhu W, Eggers P, McDougal LK, Albrecht VS. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol. 2014;52:998-1002.
11. Foucault ML, Courvalin P, Grillot-Courvalin C. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:2354-9.
12. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011;66:1057-60.
13. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755-71.
14. Beauregard DA, Williams DH, Gwynn MN, Knowles DJ. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother. 1995;39:781-5.
15. Nicas TI, Cole CT, Preston DA, Schabel AA, Nagarajan R. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989;33:1477-81.
16. Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo). 1996;49:575-81.
17. Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68:164-7.
18. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58:2921-4.
19. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(Suppl 3):S214-19.
20. Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54:5369-71.
21. Domenech O, Dufrene YF, Van Bambeke F, Tukens PM, Mingeot- Leclercq MP. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochim Biophys Acta. 2010;1798:1876-85.
22. Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53:918-25.
23. Van Bambeke F, Carryn S, Seral C, Chanteux H, Tyteca D, Mingeot-Leclercq MP, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother. 2004;48:2853-60.
24. Rodvold KA. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic 1-4 May 2004; Oral presentation 254.
25. Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, et al. Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrob Agents Chemother. 2012;56:3700-11.
26. Nguyen HA, Denis O, Vergison A, Theunis A, Tulkens PM, Struelens MJ, et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother. 2009;53:1434-42.
27. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol. 2004;4:471-8.
28. Allen NE. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Anti-Infective Agents in Medicinal Chemistry. 2010;9:23-47.
29. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother. 2005;49:1695-700.
30. Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation. Antimicrob Agents Chemother. 2014;58:2059-66.
31. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis. 2012;54(Suppl 3):S229-32.
32. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis. 2012;54(Suppl 3):S220-8.
33. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrob Agents Chemother. 2013;57:205-11.
34. Dunbar LM, Milata J, McClure T, Wasilewski MM. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55:3476-84.
35. Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis. 2012;54(Suppl 3):S239-43.
36. LaPensee K, Fan W, Good S, Jiang H, Lodise TP. A single-dose of oritavancin compared to 7-10 days of vancomycin: clinical response and safety in the MRSA subgroup treated in the ambulatory setting (solo trials). 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain 10-13 May 2014; e-Poster 415.
37. Corey R, Perez A, Moeck G, Jiang H, Good S. Single-dose oritavancin compared to 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections; the SOLO I study. 53d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, CO 10-13 September 2013; Poster L204.
38. Corey R, Perez A, Moeck G, Jiang H, Good S. Single-dose oritavancin compared to 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections; the SOLO II study. 53d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, CO 10-13 September 2013; Poster L206c.
39. Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother. 2008;9:267-83.
40. Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, et al. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis. 2013;208:1266-73.
41. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56:1418-26.
42. European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe-2012 report. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2013. p. 1-218.
43. Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother. 2009;64:353-8.
44. Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631-7.
45. Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother. 2001;48(Suppl T1):1-8.
46. Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A, Hoban DJ. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opin Emerg Drugs. 2003;8:297-321.
47. European Medicines Agency. EMEA statement on the safety of Ketek (telithromycin). 27 January 2006. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2009/11/WC500015092.pdf (accessed 13 April 2014).
48. Food and Drug Administration. Telithromycin (marketed as Ketek) information. 2007. Available at: http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htm (accessed 13 April 2014).
49. Bertrand D, Bertrand S, Neveu E, Fernandes P. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother. 2010;54:5399-402.
50. Van Bambeke F. Macrolides and ketolides. In: Vinks A, Derendorf H, Mouton JW, editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York, NY: Springer; 2014. p. 257-78.
51. English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother. 2012;56:2037-47.
52. Food and Drug Administration advisory committee. C ethromycin safe but not proven effective. 4 June 2009. Available at: http://www.healio.com/infectious-disease/practice-management/news/online/%7B3b1f728c-9639-40a2-b1fb-3eb288e17322%7D/fda-advisory-committee-cethromycin-safe-but-not-proven-effective (accesssed 13 April 2014).
53. Sato T, Tateda K, Kimura S, Iwata M, Ishii Y, Yamaguchi K. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob Agents Chemother. 2011;55:1588-93.
54. Sato T, Kawai Y, Matsuda H, Tateda K, Kimura S, Ishii Y, et al. In vitro and in vivo antibacterial activity of modithromycin against streptococci and Haemophilus influenzae. J Antimicrob Chemother. 2011;66:1547-1554.
55. Maglio D, Sun HK, Patel T, Banevicius MA, Nightingale CH, Arya A, et al. Pharmacodynamic profiling of modithromycin: Assessment in a pneumococcal murine pneumonia model. Int J Antimicrob Agents. 2014;43:540-6.
56. Oldach D, Jamieson BD, Clark K, Keedy K, Fernandes P. Systemic safety profile of solithromycin in Phase 1 & 2 clinical trials. 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A1286.
57. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010;54:4961-70.
58. Lemaire S, Van Bambeke F, Tulkens PM. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother. 2009;53:3734-43.
59. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56:5076-81.
60. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, et al. Pharmacokinetics of solithromycin (CEM-101) aft er single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother. 2011;55:1997-2003.
61. Andes DR, Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose P. Pharmacokinetic-pharmacodynamic (PK-PD) analysis of solithromycin against Streptococcus pneumoniae using data from a murine-lung infection model. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 12-15 September 2010; PosterA1-688.
62. Okusanya OO, Bhavnani SM, Forrest A, Fernandes P, Ambrose P. Pharmacokinetic-pharmacodynamic target attainment analysis supporting solithromycin (CEM-101) phase 2 dose selection. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 12-15 September 2010;PosterA1-692.
63. Okusanya OO, Bhavnani SM, Forrest A, Bulik CC, Oldach D, Fernandes P, et al. Population pharmacokinetic (PPK) and pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analyses for solithromycin (SOL, CEM-101) to support intravenous (IV). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A1269.
64. Farrell DJ, S ader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010;35:537-43.
65. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011;37:39-45.
66. Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother. 2010;54:1358-9.
67. Mallegol J, Fernandes P, Seah C, Guyard C, Melano RG. Determination of in vitro activity of solithromycin at different pHs and its intracellular activity tested against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]
68. Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis. 2013;13:40.
69. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother. 2012;56:2739-42.
70. Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide resistant and susceptible Mycoplasma genitalium strains. Antimicrob Agents Chemother. 2014;58:3151-6.
71. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53:2139-41.
72. Lemaire S, van der Linden M, Tulkens PM. Activity of solithromycin against clinical isolates of S. pneumoniae with variable susceptibilities to conventional antibiotics. 28th International Congress on Chemotherapy and Infection, Yokoama, Japan, 5-8 June 2013; Poster105.
73. Biedenbach DJ, Sader HS, Jones RN, Farrell DJ. Antimicrobial activity of solithromycin (CEM-101), a novel fluoroketolide, tested against isolates collected in Europe during 2010 surveillance. 21th European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy, Milan, Italy, 7-10 May 2011; Poster1136.
74. Vandevelde NM, Tulkens PM, Van Bambeke F. Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2014;58:1348-58.
75. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526-34.
76. Emami S, Shafiee A, Forounmadi A. Quinolones: recent structural and clinical developments. Ir J Pharm Res. 2005;4:123-36.
77. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005;11:256-80.
78. Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. J Antibiot (Tokyo). 2014;67:7-22.
79. Sousa J, Alves G, Fortuna A, Falcao A. Third- and fourth-generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf. 2014 Jan 6. [Epub ahead of print]
80. Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis. 2006;42:1598-607.
81. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32:359-78.
82. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61:377-92.
83. Munoz-Bellido JL, Alonzo MM, Martinez Andres JA, Guttierrez Zufiaurre MN, Ortiz G, Segovia HM, et al. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother. 1999;43:354-6.
84. Costa SS, Falcao C, Viveiros M, Machado D, Martins M, Melo-Cristino J, et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol. 2011;11:241.
85. Alam MM, Kobayashi N, Uehara N, Watanabe N. Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus. Microb Drug Resist. 2003;9:109-21.
86. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:187-9.
87. Garvey MI, Baylay AJ, Wong RL, Piddock LJ. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2011;55:190-6.
88. Lismond A, Carbonnelle S, Tulkens PM, Van Bambeke F. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia. J Antimicrob Chemother. 2011;66:948-51.
89. Schmitz FJ, Fluit AC, Luckefahr M, Engler B, Hofmann B, Verhoef J, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998;42:807-10.
90. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother. 2003;51:1055-65.
91. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS, et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999;43:1340-6.
92. Tran J H, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A. 2002;99:5638-42.
93. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83-8.
94. Dalhoff A. Resistance surveillance studies: a multifaceted problem - the fluoroquinolone example. Infection. 2012;40:239-62.
95. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.
96. Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS. 2011;119:853-63.
97. Van Heirstraeten L, Leten G, Lammens C, Goossens H, Malhotra-Kumar S. Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10. J Antimicrob Chemother. 2012;67:2602-5.
98. Lemaire S, Van Bambeke F, Tulkens PM. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. Int J Antimicrob Agents. 2011;38:52-9.
99. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacinsensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother. 2010;54:1613-15.
100. Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J Antimicrob Chemother. 2010;65:2530-3.
101. Stubbings W, Leow P, Yong GC, Goh F, Korber-Irrgang B, Kresken M, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother. 2011;55:4394-7.
102. Dalhoff A, Stubbings W, Schubert S. Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob Agents Chemother. 2011;55:1814-18.
103. Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, Seiberling M, et al. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2011;55:4386-93.
104. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-96.
105. Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39:321-5.
106. Biedenbach DJ, Turner LL, Jones RN, Farrell DJ. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. Diagn Microbiol Infect Dis. 2012;74:204-6.
107. Eichenbaum G, Pugsley MK, Gallacher DJ, Towart R, McIntyre G, Shukla U, et al. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br J Pharmacol. 2012;166:1694-707.
108. Van Wart SA, Melhem M, Davenport JM, Ambrose P, Bhavnani SM, Andes DR, et al. Population pharmacokinetic (PPK) and pharma-cokinetic- pharmacodynamic (PK-PD) target attainment (TA) analyses to support JNJ-Q2 dose selection for patients with acute bacterial skin and skin structure infections (ABSSSI). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A-1961.
109. Davenport JM, Covington PS, Gotfried MH, Medlock M, Watanalumlerd P, McIntyre G, et al. Summary of pharmacokinetics and tissue distribution of a broad-spectrum fluoroquinolone, JNJ-Q2. Clin Pharmacol Drug Dev. 2012;1:121-30.
110. Covington PS, Davenport JM, Andrae DA, Stryjewski ME, Turner LL, McIntyre G, et al. A phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia. J Antimicrob Chemother. 2013;68:2691-3.
111. Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents. 2010;36:97-8.
112. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother. 2006;50:2261-4.
113. Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA. Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Diagn Microbiol Infect Dis. 2008;62:110-12.
114. Han H, Kim SE, Shin KH, Lim C, Lim KS, Yu KS, et al. Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet. Curr Med Res Opin. 2013;29:1349-55.
115. Kim YS, Kim MJ, Back KR, Lim CH, Rock JA, Seong SK, et al. A phase 2, multi-dose, double-blind, randomized, multicenter, safety and efficacy study of zabofloxacin vs moxifloxacin in the treatment of mild to moderate community-acquired pneumonia. 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster L1-294.
116. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009;53:4915-20.
117. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58:1800-1.
118. Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012;56:3943-9.
119. Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:405-10.
120. Chung DT, Tsai CY, Chen SJ, Chang LW, King CH, Hsu CH, et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother. 2010;54:411-17.
121. Liang W, Chen YC, Cao YR, Liu XF, Huang J, Hu JL, et al. Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 2013;57:2942-7.
122. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-83.
123. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098-106.
124. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:649-58.
125. Duffy E, Devito JA, Remy J, Burak E. Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens II. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 12-15 September 2010; Poster E183.
126. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44:681-8.
127. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67:2814-20.
128. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57:2726-37.
129. Burak E, Hopkins S, Pillar C, Lawrence L. In vitro activity of delaoxacin against methicillin-resistant Staphylococcus aureus from the United States, Europe and Asia. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 16-19 May 2009; Poster1080.
130. Ding Y, Villet MA, Lee JC, Hooper DC. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. 21th European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy, Milan, Italy, 7-10 May 2011; Poster 1506.
131. Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Burak E. Evaluation of delafloxacin in rat granuloma pouch infections caused by Gram-negative pathogens. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 12-15 September 2010; Poster A1-680.
132. Lawrence L, Benedict M, Hart J, Hawkins A, Danping L, Medlock M, et al. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. 51th Interescience Conference on Antimicrobial Agents and Chemotherpay, Chicago, IL, 17-20 September 2011; Poster A2-045a.
133. Rubino CM, Bhavnani SM, Burak E, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analyses supporting delafloxacin phase 3 dose regimen decisions. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 12-15 September 2010; Poster A1-681.
134. Hoover R, Lawrence L, Longcor J, Greenfield J. Pharmacokinetics (PK) of delafloxacin (DLX), vancomycin (VAN), and linezolid (LNZ) in a phase 2 exploratory study in subjects with acute bacterial skin and skin structure infections (ABSSSI). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A1957.
135. Lawrence L, Longcor J, Li D, Reeve M, Hoover R, McEwen AB, et al. Metabolism and mass balance of [14C]-Delafloxacin in healthy human volunteers following intravenous administration. 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A1956.
136. Hoover R, Lawrence L, Smith C, Longcor J. Pharmacokinetics (PK) of delafloxacin (DLX) in patients with varying degrees of renal impairment. 53d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, CO, 10-13 September 2013; Poster A-017E.
137. Burak E, Bortolon E, Molstad D, Wu Y, Jing H, Girard D. Pharmacokinetics and pharmacodynamics of delafloxacin in S. aureus murine thigh infection models. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 12-15 September 2009; Poster A1-1941.
138. Longcor J, Hopkins S, Lawrence L, Green S, Mahra P, Manos P, et al. Results of a phase 2 study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster L1-1663.
139. Lawrence L, Benedict M, Litwin J, Thorn M, Medlock M, Hopkins S, et al. A thorough phase 1 QTc study of delafloxacin (DLX) compared with placebo and moxifloxacin (MXF). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster A1958.
140. Longcor J, Lawrence L, Duffy E, Hopkins S. O bjective measures of clinical efficacy in a phase 2b exploratory study of delafloxacin compared to vancomycin and linezolid in adults with acute bacterial skin and skin structure infections (ABSSSI). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012; Poster L1-1667c.
141. Roberts MC, Remy J, Longcor J, Marra A, Sun E, Duffy E. In vitro activity of delafloxacin against Neisseria gonorrhoeae clinical isolates. STI & AIDS World Congress 2013, Vienna, Austria, 14-17 June 2013; Poster.
142. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012;55:1031-46.
143. Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents. 2010;36:69-72.
144. Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009;53:4762-71.
145. Farrell DJ, Castanheira M, Sader HS, Jones RN. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J Infect. 2010;61:476-83.
146. Andrews JM, Weller TM, Ashby JP, Walker RM, Wise R. The in vitro activity of ABT773, a new ketolide antimicrobial agent. J Antimicrob Chemother. 2000;46:1017-22.
147. Luna VA, Xu ZQ, Eiznhamer DA, Cannons AC, Cattani J. Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin. J Antimicrob Chemother. 2008;62:639-40.
148. Arhin FF, Sarmiento I, Parr TR Jr, Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother. 2009;64:868-70.
149. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother. 2009;64:1226-9.
150. Singh KV, Malathum K, Murray BE. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci. Antimicrob Agents Chemother. 2001;45:3640-3.
151. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54:1338-42.
152. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011;55:3631-4.
153. Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother. 2006;58:684-8.
154. Burak E, Devito JA, Remy J, Duffy E. Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens I. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 12-15 September 2010; Poster E182.
155. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 2010;54:1955-64.
156. Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrob Agents Chemother. 2012;56:1639-42.
157. Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, et al. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob Agents Chemother. 2006;50:2064-71.
158. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, et al. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010;54:230-8.